Clinical and molecular features of <scp> <i>FLT3</i> </scp> juxtamembrane domain missense mutations in acute myeloid leukaemia-Reference-Cited by-同舟云学术

Clinical and molecular features of FLT3 juxtamembrane domain missense mutations in acute myeloid leukaemia

Published:2022-11-28 Issue:24 Volume:26 Page:6079-6082
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Jensen Christopher E.¹²^ORCID,Montgomery Nathan D.³⁴,Galeotti Jonathan³,Foster Matthew C.¹⁵,Zeidner Joshua F.¹⁵

Affiliation:

1. Divisions of Hematology and Oncology, Department of Internal Medicine University of North Carolina School of Medicine Chapel Hill North Carolina USA

2. Cecil G. Sheps Center for Health Services Research University of North Carolina Chapel Hill North Carolina USA

3. Department of Pathology and Laboratory Medicine University of North Carolina School of Medicine Chapel Hill North Carolina USA

4. Tempus‐RTP Durham North Carolina USA

5. Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill North Carolina USA

Funder

Agency for Healthcare Research and Quality

Publisher

Wiley

Subject

Cell Biology,Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.17608

Reference14 articles.

1. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.

2. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

3. The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane Domain

4. Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

5. Genomic Classification and Prognosis in Acute Myeloid Leukemia